Docoh
Loading...

BRTX BioRestorative Therapies

Filed: 19 Nov 21, 1:01pm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K


Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 16, 2021


BioRestorative Therapies, Inc.
(Exact Name of Registrant as Specified in Its Charter)


001-37603
(Commission File Number)

Delaware
91-1835664
(State or Other Jurisdiction of Incorporation)(I.R.S. Employer Identification No.)

40 MARCUS DRIVE
MELVILLE, New York 11747
(Address of principal executive offices, including zip code)

(631) 760-8100
(Registrant’s telephone number, including area code)

NOT APPLICABLE
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class 
Trading
Symbol(s)
 Name of each exchange on which registered
Common Stock, $0.0001 par value

BRTX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Pursuant to authority granted by the stockholders of BioRestorative Therapies, Inc. (the “Company”), in connection with the Company’s 1-for-4,000 reverse split of the Company’s issued and outstanding common stock effected as of October 27, 2021 (the “Reverse Split”), the Board of Directors has approved a reduction in the number of shares of common stock authorized to be issued by the Company from 300,000,000,000 to 75,000,000 (the “Authorized Shares Reduction”). The Authorized Shares Reduction is consistent with the Reverse Split ratio.

On November 16, 2021, the Company filed a Certificate of Amendment with the Secretary of State of the State of Delaware to effect the Authorized Shares Reduction.  A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.
 
Item 9.01.Financial Statements and Exhibits.

(d) Exhibits:

3.1 Certificate of Amendment


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 BIORESTORATIVE THERAPIES, INC.
 
    
Dated:  November 18, 2021
By:/s/ Lance Alstodt
 
  Lance Alstodt
 
  Chief Executive Officer